Business Wire

Thales to Provide Mobile Driver Licenses to State of Florida

13.10.2020 16:00:00 EEST | Business Wire | Press release

Share

The State of Florida will be the first state in the United States to provide mobile Driver Licenses with leading-edge security mechanisms, fully compliant with rigorous national and international standards. Thales will supply the Florida Department of Highway Safety and Motor Vehicles with mobile Driver License verification services, as well as a mobile Driver License solution for residents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005021/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In 2021, Florida residents will be able to apply for new mobile Driver Licenses that are easily accessible on a variety of devices, including smartphones and tablets. These mobile Driver Licenses meet the national and international standards from the American Association of Motor Vehicle Administrators and the International Organization for Standardization, meaning they can be used across the United States and internationally.

These new mobile Driver Licenses have the same validity as traditional driver’s licenses to verify identity, including proof of age and driving privileges. It also provides an additional role as a strong authentication tool, enabling Floridians to securely prove who they are online for a variety of services.

Now, to complement the traditional use of driver licenses to prove their identity, Florida residents will be able to simply activate their mobile identification application, select the type of verification needed, and hold up their mobile device. The mobile device never leaves the owners hand, making it a contact-free and convenient way to show ID.

“I’m excited for this innovation project that will make the state of Florida a national leader in offering secure and trusted mobile identification, which is a priority for our Governor, Ron DeSantis,” said Terry L. Rhodes, Executive Director of the Florida Department of Highway Safety and Motor Vehicles. “We have made a sustained commitment to the modernization of nearly every aspect of what our department does and how customers access our services, and Thales will be a great partner as Florida now steps into the future of mobile identification.”

“As ID fraud becomes more frequent and sophisticated, we made it a priority to reinforce ID verification by adding extra software security technologies. In the future, enterprises such as airports, hotels, car rental companies etc, in Florida will be able to rely on Thales to identify customers, while guaranteeing their privacy”, said Tony Lo Brutto, VP NORAM, Identity and Biometric Solutions at Thales.

These mobile Driver Licenses are harder to counterfeit, as they host a secure digitized credential whose authenticity can be checked rather than simply displaying a digital image of a driver license that could be easily manipulated.

For stronger privacy, users of mobile Driver Licenses control what information is displayed from the app depending on the context. For example, to enter a casino it only needs to show that the individual is old enough and the mobile Driver License will just display that information – not the individual’s name, date of birth, or address.

The Florida mobile Driver License program builds on Thales’ strong foundation of supporting state identity programs for 11 other U.S. states and five Canadian provinces.

Note to Editors

Thales, a leader in mobile driver’s license technology, successfully conducted the first U.S. mobile Driver’s License or Digital Driver’s License pilots across multiple states through a partnership and grant awarded in 2016 by the U.S. National Institute of Standards and Technology. Thales has recently been nationally recognized for the Digital ID Wallet, which incorporates the mobile Driver’s License solution, by Frost & Sullivan and ABI Research

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT
Thales Group
Download HD pictures

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations

Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
Vanessa.viala@thalesgroup.com

Thales, Media Relations
USA
Adam Kostecki
+1 (703) 838-5645
adam.kostecki@us.thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release

Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release

Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release

Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye